Abstract:Triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane receptor protein predominantly expressed in microglia within the central nervous system (CNS). TREM2 regulates multiple microglial functions, including lipid metabolism, immune reaction, inflammation, and microglial phagocytosis. Recent studies have found that TREM2 is highly expressed in activated microglia after ischemic stroke. However, the role of TREM2 in the pathologic response after stroke remains unclear. Herein, TREM2-deficient microglia exhibit an impaired phagocytosis rate and cholesteryl ester (CE) accumulation, leading to lipid droplet formation and upregulation of Perilipin-2 (PLIN2) expression after hypoxia. Knockdown of TREM2 results in increased lipid synthesis (PLIN2, SOAT1) and decreased cholesterol clearance and lipid hydrolysis (LIPA, ApoE, ABCA1, NECH1, and NPC2), further impacting microglial phenotypes. In these lipid droplet-rich microglia, the TGF-β1/Smad2/3 signaling pathway is downregulated, driving microglia towards a pro-inflammatory phenotype. Meanwhile, in a neuron-microglia co-culture system under hypoxic conditions, we found that microglia lost their protective effect against neuronal injury and apoptosis when TREM2 was knocked down. Under in vivo conditions, TREM2 knockdown mice express lower TGF-β1 expression levels and a lower number of anti-inflammatory M2 phenotype microglia, resulting in increased cerebral infarct size, exacerbated neuronal apoptosis, and aggravated neuronal impairment. Our work suggests that TREM2 attenuates stroke-induced neuroinflammation by modulating the TGF-β1/Smad2/3 signaling pathway. TREM2 may play a direct role in the regulation of inflammation and also exert an influence on the post-ischemic inflammation and the stroke pathology progression via regulation of lipid metabolism processes. Thus, underscoring the therapeutic potential of TREM2 agonists in ischemic stroke and making TREM2 an attractive new clinical target for the treatment of ischemic stroke and other inflammation-related diseases.

TREM2 Regulates Microglial Phagocytosis of Synapses in Innate Immune Tolerance

TMEM59 Interacts with TREM2 and Modulates TREM2-dependent Microglial Activities

TREM2 inhibits inflammatory responses in mouse microglia by suppressing the PI3K/NF-κB signaling

TREM2 Regulates Innate Immunity in Alzheimer’s Disease

TREM2 Regulates Microglial Cholesterol Metabolism Upon Chronic Phagocytic Challenge

TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease

Opposing Roles of the Triggering Receptor Expressed on Myeloid Cells 2 and Triggering Receptor Expressed on Myeloid Cells-Like Transcript 2 in Microglia Activation.

Consecutive Injection of High-Dose Lipopolysaccharide Modulates Microglia Polarization via TREM2 to Alter Status of Septic Mice

TREM2/DAP12 Complex Regulates Inflammatory Responses in Microglia via the JNK Signaling Pathway.

Regulation Of Trem2 Expression By An Nf-Kappa B-Sensitive Mirna-34a

The Alzheimer’s disease-associated gene TREML2 modulates inflammation by regulating microglia polarization and NLRP3 inflammasome activation

Distinct myeloid population phenotypes dependent on TREM2 expression levels shape the pathology of traumatic versus demyelinating CNS disorders

TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism

TREM2 regulates microglial lipid droplet formation and represses post-ischemic brain injury

Elevating Microglia TREM2 Reduces Amyloid Seeding and Suppresses Disease-Associated Microglia

TREM2 Regulates High Glucose-Induced Microglial Inflammation via the NLRP3 Signaling Pathway

TREM2 promotes Aβ phagocytosis by upregulating C/EBPα-dependent CD36 expression in microglia

TPM1 mediates inflammation downstream of TREM2 via the PKA/CREB signaling pathway

Soluble TREM2 Induces Inflammatory Responses and Enhances Microglial Survival

TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration

TREM2 in CNS Homeostasis and Neurodegenerative Disease